oasis 1 oral semaglutide 50 mg obesity lancet 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial GLP-1 Receptor Agonists for Weight
Description
Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity.
This peptide has achieved an average of 15% body weight loss in clinical trials
01185-6/asset/2164201a-96aa-45fd-b531-5fbac7f670fe/main.assets/gr2.jpg)
41.5% had a history of MI or stroke
What we know (and dont know) about GLP-1 drugs, fertility, and birth control
Why 3 months matters
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist
01479-4/asset/ceb1b864-8d05-4965-881e-ee8f620d56aa/main.assets/fx1.jpg)
